Capsule Summary Slidesets

Share

Program Content

Activities

  • MONALEESA Pooled Analysis
    Biomarkers of Response or Resistance to Ribociclib + Endocrine Therapy for Advanced Breast Cancer: Pooled Analysis of MONALEESA Phase III Trials
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 31, 2020

    Expires: May 30, 2021

  • CompLEEment-1
    CompLEEment-1: Updated Results From the Phase IIIb Study of Ribociclib Plus Letrozole in HR+, HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • KEYNOTE-355 Safety + Efficacy
    KEYNOTE-355: Pembrolizumab + Chemotherapy for Previously Untreated Advanced Triple-Negative Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • SOLO2 Final OS Analysis
    SOLO2: Final OS Analysis of Maintenance Olaparib in Platinum-Sensitive, Relapsed Ovarian Cancer with BRCA Mutation
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • Niraparib Dosing
    Optimal Dosing of the Poly(ADP-Ribose) Polymerase Inhibitor Niraparib
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • HER2CLIMB CNS Analysis
    HER2CLIMB: Tucatinib Plus Trastuzumab and Capecitabine in Previously Treated HER2-Positive MBC With Brain Metastases
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2020

    Expires: June 01, 2021

  • DESKTOP III: Surgery in PSROC
    DESKTOP III: Improved Survival With Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2020

    Expires: June 02, 2021

  • BYLieve: Alpelisib After CDK4/6i
    Phase II BYLieve: Alpelisib Plus Fulvestrant in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitor Plus AI
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2020

    Expires: June 02, 2021

  • MONALEESA-3/-7 Pooled
    MONALEESA-3/-7 Pooled OS Analysis: Ribociclib Plus ET in Patients With HR+/HER2- Advanced Breast Cancer and Visceral Metastases
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2020

    Expires: June 02, 2021

  • SWOG 1416: Plt Plus PARPi
    Phase II SWOG 1416: Cisplatin Plus Veliparib or Placebo in Metastatic TNBC and BRCA Mutation–Associated Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2020

    Expires: June 03, 2021

  • Lenvatinib/Pembrolizumab
    KEYNOTE-146: Lenvatinib Plus Pembrolizumab as Early-Line Treatment of Advanced Endometrial Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2020

    Expires: June 04, 2021

  • KEYNOTE-100
    KEYNOTE-100: Final Results From Phase II Study on Pembrolizumab Monotherapy for Advanced Recurrent Ovarian Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2020

    Expires: June 07, 2021

  • AVANOVA2 Update
    AVANOVA2 Extended Follow-up: Niraparib Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2020

    Expires: June 07, 2021

  • E2108: Local Tx in de novo MBC
    ECOG-ACRIN 2108: Phase III Trial Evaluating the Role of Early Local Therapy for Patients With Metastatic Breast Cancer and an Intact Primary Tumor
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2020

    Expires: June 08, 2021

Provided by

ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono